Skip to main content
A Singapore Government Agency Website How to identify
Official website links end with .gov.sg
Government agencies communicate via .gov.sg websites (e.g. go.gov.sg/open). Trusted websites
Secure websites use HTTPS
Look for a lock () or https:// as an added precaution. Share sensitive information only on official, secure websites.

Government officials will never ask you to transfer money or disclose bank log-in details over a phone call.

Call the 24/7 ScamShield Helpline at 1799 if you are unsure if something is a scam.

Agency for Care Effectiveness
Drug guidance

Blinatumomab for treating relapsed or refractory B-precursor acute lymphoblastic leukaemia

Condition

Blood and Immune System

Cancer

1 April 2026

Published on 01 Sep 2020
Last Updated on 01 Apr 2026

Guidance Recommendations

The Ministry of Health’s Drug Advisory Committee has recommended:

  • Blinatumomab 35 mcg powder for infusion for treating relapsed or refractory B-precursor acute lymphoblastic leukaemia (r/r B-ALL) for:

    • up to a maximum of two cycles for induction in a lifetime; and

    • up to three additional cycles for consolidation in a lifetime in patients who achieve a complete response after induction.

Subsidy status

Blinatumomab 35 mcg powder for infusion is recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indication from 1 September 2020.

Clinical indication, subsidy class and MediShield Life claim limit for blinatumomab are provided in the Annex.

Blinatumomab for treating relapsed or refractory B-precursor acute lymphoblastic leukaemia (Updated 1 Apr 2026) [PDF, 177 KB]

PES Blinatumomab for treating relapsed or refractory B-precursor acute lymphoblastic leukaemia (Updated 1 Apr 2026) [PDF, 133 KB]

Back to top